Release date: 2024-08-15 17:46:30 Article From: Lucius Laos Recommended: 128
As a RET gene-targeted drug, Selpercatinib can effectively treat RET-related cancers; By inhibiting key signaling pathways, it inhibits the spread and invasion of cancer cells. It can be used in both adults and adolescents.
The packaging specification of Selpercatinib produced by Lucius is 40mg*120 capsules, and the market price is about 3,375 yuan. Bangladesh Everest Pharmaceutical's Selpercatinib is 40mg*30 capsules per box, and the price is about 2,200 yuan.
The above prices are for reference only, and patients must strictly follow the doctor's guidance when deciding to use Selpercatinib. Before prescribing drugs, the doctor will comprehensively evaluate the patient's condition, age, liver and kidney function, etc., and formulate a personalized medication plan.
As a targeted drug, selpatinib will inevitably have some adverse reactions during treatment, which are summarized as follows according to the drug instructions:
Many patients experience extreme exhaustion during treatment and a significant decrease in their ability to perform daily activities. To cope with fatigue, patients should ensure adequate rest periods, do what they can during activity, and avoid overexertion.
Some patients may notice a change in the taste of food, a taste disorder that may lead to loss of appetite. To improve the eating experience, patients can try different flavors of food or increase the flavoring of food to stimulate appetite.
In strict accordance with EU pharmaceutical standards, Lucius Pharmaceutical has introduced advanced equipment for the production of anti-tumor, antiviral, biologics, cephalosporins and commonly used drugs. The company is committed to scientific research and innovation, and continues to explore new areas of drug research and development. It brings together a first-class scientific research team and advanced technology platform.
Lucius Pharmaceuticals drives breakthroughs in the field of medicine through in-depth research and innovation. Lucius's research not only provides more effective treatment options, but also breathes new life into the industry. Lucius Pharmaceuticals firmly believes that continuous scientific research and innovation is the core driving force for enterprise development and the key to serving human health.
[Warm tips] Even if you feel that your condition is improving, do not stop the medicine on your own, please follow the doctor's instructions to complete the entire course of treatment.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: